Hepatitis B virus triggers cell 'suicide' in patients with chronic infection

Scientists from UCL (University College London) have identified a key difference between people who can fight the Hepatitis B virus (HBV) off successfully and those who fail to do so – that a group of cells important in controlling the disease are triggered to ‘commit suicide’ in patients who are chronically infected. This discovery provides an important new focus for developing therapies or vaccines that boost the body’s ability to manage this infection.

The researchers analysed thousands of genes in T cells, critical players of the immune system required for control of HBV. They found that T cells from patients who were chronically infected were triggered to ‘commit suicide’. This could be an important factor in determining why these patients’ immune systems cannot fight the infection, and a process which could be a useful target for new treatments. Their findings are published today in the Journal of Clinical Investigation.

Hepatitis B virus (HBV) is one of the most common viruses in the world, and ranks as one of the top ten killer infectious diseases. More than 350 million people have long-term infection with HBV, which may lead to liver cirrhosis, liver failure or liver cancer. In the majority of adults infected, the immune system is able to control the virus very well and is, in fact, more effective than any currently available treatment. Understanding what goes wrong in people with chronic infection is crucial to the development of new therapies.

Lead author, Dr Mala Maini, UCL Division of Infection & Immunity, said: “We used microarray gene chips to screen more than 5,000 genes in T cells from both recovered and chronically infected Hepatitis B patients. This led to the discovery that, instead of successfully reacting to the virus, the T cells in the latter group were triggered to commit suicide by one of the cells’ own death-inducing proteins, called ‘Bim’. We are now looking into the fine mechanism driving this outcome.”

The paper’s first author, Ross Lopes, added: “If we can develop safe ways of blocking the suicidal tendency of the T cells, we may be able to prolong their survival, so they can do a better job of controlling Hepatitis B infection.”

The proportion of the world's population currently infected with HBV is estimated at between 3 and 6 per cent, but up to a third have been exposed. It is endemic in parts of Asia and Africa. Chronic Hepatitis B may eventually cause liver cirrhosis and liver cancer, a fatal disease with very poor response to current treatments. The infection is preventable by vaccination at a young age.

Source: University College London

Related stories:

Scientists Find First Immune Responses to HIV Infection Ineffective
(PhysOrg.com) -- Scientists have identified the very first antibodies to appear in the wake of HIV infection and have concluded that they are virtually impotent in mounting a meaningful defense against the invading virus.
Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.
Wistar researchers invigorate 'exhausted' immune cells
In battles against chronic infections, the body's key immune cells often become exhausted and ineffective. Researchers at The Wistar Institute have found a way to restore vigor to these killer T cells by blocking a key receptor on their surface, findings that may advance the development of new therapies for diseases such as HIV, hepatitis B and C, and cancer.
A potential approach to treatment of hepatitis B virus infection
Eukaryotic cells employ multiple strategies of checkpoint signaling and DNA repair mechanisms to monitor and repair damaged DNA. There are two branches in the checkpoint response pathway—ataxia telangiectasia-mutated (ATM) and ATM-Rad3-related (ATR). Many viruses are now known to interact with DNA damage sensing and repair machinery.
To protect against liver disease, body puts cells 'under arrest'
A stable form of cell-cycle arrest known to offer potent protection against cancer also limits liver fibrosis, a condition characterized by an excess of fibrous tissue, according to a new report in the August 22nd Cell, a Cell Press publication. Triggered by chronic liver damage produced by hepatitis infection, alcohol abuse, or fatty liver disease, liver fibrosis can lead to cirrhosis, a major health problem worldwide and the 12th most common cause of death in the United States.
Trapping white blood cells proves novel strategy against chronic viral infections
Seeing disease-fighting white blood cells vanish from the blood usually signals a weakened immune system. But preventing white blood cells' circulation by trapping them in the lymph nodes can help mice get rid of a chronic viral infection, researchers at Yerkes National Primate Research Center and the Emory Vaccine Center have found.
Liver damage in hepatitis C patients could be treated with warfarin, says study
The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.
Liver damage in Hepatitis C patients could be treated with warfarin, says new study
The drug warfarin may help prevent liver failure in thousands of people with Hepatitis C, according to new research.

News discussion:

Medicine & Health news